TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7705096

Group type: EXPERIMENTAL
Intervention: CVR releasing 30 mcg of ethinyl estradiol and 650 mcg of norethindrone acetate (30/650)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CVR releasing 20 mcg of ethinyl estradiol and 1000 mcg of norethindrone acetate (20/1000)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CVR releasing 25 mcg of ethinyl estradiol and 650 mcg of norethindrone acetate (25/650)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oral contraceptive containing norethindrone acetate/ethinyl estradiol
Number of subjects: 69
Study: 3556264

Group type: EXPERIMENTAL
Intervention: Paracetamol/codeine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Paracetamol/dextropropoxyphene
Number of subjects: 85
Study: 31486133

Group type: EXPERIMENTAL
Intervention: Interstitial laser therapy (Nd‐YAG laser) performed under sonographic control
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: No procedure related complications
Number of subjects: 12
Study: 28389158

Group type: EXPERIMENTAL
Intervention: Basal insulin (insulin glargine)
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Biphasic insulin (insulin lispro mixture)
Number of subjects: 2931

Group type: COMPARATOR
Intervention: No hypoglycemia
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Mild hypoglycemia rate/month
Number of subjects: 2931
Study: 25469720

Group type: EXPERIMENTAL
Intervention: 19-mg iron pills
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: 38-mg iron pills
Number of subjects: 692

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692

Group type: COMPARATOR
Intervention: Educational group (letters thanking for donation)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Educational group (suggesting iron supplements or delayed donation)
Number of subjects: 692
Study: 24190680

Group type: EXPERIMENTAL
Intervention: Increase sleep condition
Number of subjects: 37

Group type: COMPARATOR
Intervention: Decrease sleep condition
Number of subjects: 37
Study: 22018294

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1443
Study: 18837797

Group type: EXPERIMENTAL
Intervention: Dysglycaemia in primary normoglycaemic ESRD patients on MHD
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes diagnosis in dysglycaemia patients
Number of subjects: 239

Group type: COMPARATOR
Intervention: Comparison with matched control MHD patients
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Increment in HbA1c
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Event-free survival in dysglycaemia patients
Number of subjects: 239
Study: 17158426

Group type: EXPERIMENTAL
Intervention: High-dose oral cyanocobalamin (1000 microg/d) for 3 months
Number of subjects: 149

Group type: COMPARATOR
Intervention: Normal MMA group with 0 microg cyanocobalamin/d
Number of subjects: 149

Group type: COMPARATOR
Intervention: Normal MMA group with 25 microg cyanocobalamin/d
Number of subjects: 149

Group type: COMPARATOR
Intervention: Normal MMA group with 100 microg cyanocobalamin/d
Number of subjects: 149
Study: 12914120

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg i.v. every 8 hours
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin 500 mg i.v. every 8 hours
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g i.v. every 12 hours plus metronidazol 500 mg twice daily
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Cefoperazone/sulbactam 2 g daily administered every 12 hours
Number of subjects: 468

Group type: COMPARATOR
Intervention: Cefoperazone/sulbactam
Number of subjects: 468

Group type: COMPARATOR
Intervention: Cefepime plus metronidazol
Number of subjects: 468

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 468

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 468

Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 468
Study: 11920167

Group type: EXPERIMENTAL
Intervention: Homozygous factor V Leiden women
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 64
Study: 9228508

Group type: EXPERIMENTAL
Intervention: Standard liquid diet (Biosorb Sonde)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fibre containing diet (Biosorb Plus Sonde)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate modified, fructose containing 'diabetes' diet (Fresubin Diabetes)
Number of subjects: 10
Study: 8144244

Group type: EXPERIMENTAL
Intervention: Kloroperka
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 0

Group type: COMPARATOR
Intervention: ProcoSol
Number of subjects: 0
Study: 3539737

Group type: EXPERIMENTAL
Intervention: BAY m 1099 (alpha-glucosidase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30100279

Group type: EXPERIMENTAL
Intervention: Maitland Mobilization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization with Movement (MWM)
Number of subjects: 30
Study: 26183139

Group type: EXPERIMENTAL
Intervention: Regenerex
Number of subjects: 60

Group type: COMPARATOR
Intervention: PPS
Number of subjects: 60
Study: 24807721

Group type: EXPERIMENTAL
Intervention: ALVAC/AIDSVax vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C1 and V2 monoclonal antibodies isolated from RV144 vaccinees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: V2 monoclonal antibody CH58
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low IgA Env antibody levels
Number of subjects: 0
Study: 22928374

Group type: EXPERIMENTAL
Intervention: Home bleaching with 10% carbamide peroxide (CP) for 4 hours a day, over the course of 3 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) with three 10-minute applications at each session and no light source
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) with quartz‐tungsten‐halogen light irradiation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) with LED/laser light irradiation
Number of subjects: 40
Study: 20950416

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Radiation alone (RT)
Number of subjects: 1608
Study: 17632400

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 43
Study: 15755303

Group type: EXPERIMENTAL
Intervention: Video feedback and personal book
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Personal book only
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study: 12194122

Group type: COMPARATOR
Intervention: Placebo (vaseline)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 10% lidocaine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 5% prilocaine‐5% lidocaine (EMLA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 0.2% glyceryl trinitrate ointment (GTN)
Number of subjects: 102
Study: 9472426

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Secobarbital 100 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison group (natural sleep)
Number of subjects: 40
Study: 8585581

Group type: EXPERIMENTAL
Intervention: Multivitamin containing folic acid
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Multivitamin containing folic acid (after controlling for confounding factors)
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Cereal containing folic acid
Number of subjects: 866

Group type: COMPARATOR
Intervention: No multivitamin use
Number of subjects: 866
Study: 2744186

Group type: EXPERIMENTAL
Intervention: Anandron (100 mg twice a day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Anandron
Number of subjects: 18
Study: 1086117

Group type: EXPERIMENTAL
Intervention: Fibre‐optic endoscopy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Double‐contrast radiology
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fibre‐optic endoscopy and double‐contrast radiology
Number of subjects: 53
Study: 31288877

Group type: EXPERIMENTAL
Intervention: Modified barbed pharyngoplasty
Number of subjects: 34

Group type: COMPARATOR
Intervention: Barbed pharyngoplasty
Number of subjects: 34
Study: 28594587

Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (IND/GLY)
Number of subjects: 6108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6108
Study: 26908303

Group type: EXPERIMENTAL
Intervention: D‐methadone 40 mg PO twice daily for 12 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D‐methadone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D‐methadone 40 mg PO Q 12 hours
Number of subjects: 10
Study: 24945621

Group type: EXPERIMENTAL
Intervention: Burst stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: 500-Hz tonic stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 20
Study: 22574588

Group type: EXPERIMENTAL
Intervention: ETV combined with SY
Number of subjects: 164

Group type: COMPARATOR
Intervention: ETV
Number of subjects: 164
Study: 20005692

Group type: EXPERIMENTAL
Intervention: Substance abuser
Number of subjects: 516

Group type: COMPARATOR
Intervention: Substance use disorder
Number of subjects: 516
Study: 17082463

Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (PB) 500 mg/kg/day, intermittent regimen (7 days on/7 days off) for 13 weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (PB)
Number of subjects: 107
Study: 16120154

Group type: EXPERIMENTAL
Intervention: 2% progesterone cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 40
Study: 12486461

Group type: EXPERIMENTAL
Intervention: Japan's articles in orthopedics
Number of subjects: 878

Group type: COMPARATOR
Intervention: Total articles published in orthopedics journals
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Japan's contribution to orthopedics research
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Quality of clinical research studies in Japan
Number of subjects: 878
Study: 10584982

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg) at a concentration of 10 mg/mL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (lymphocytes of pregnant women not at risk of abortion)
Number of subjects: 20
Study: 8543703

Group type: EXPERIMENTAL
Intervention: Self-help booklet alone
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Self-help booklet with computer-generated personalized feedback
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Self-help booklet, personalized feedback, and outreach telephone counseling
Number of subjects: 1137

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 1137
Study: 1516608

Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol base in aerosol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 micrograms of powder
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol (both forms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol powder
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol MDI
Number of subjects: 12
Study: 6509946

Group type: EXPERIMENTAL
Intervention: Oral gold
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Injectable gold
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 30730481

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training
Number of subjects: 402

Group type: COMPARATOR
Intervention: Arthritis Education
Number of subjects: 402

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 402
Study: 29095431

Group type: EXPERIMENTAL
Intervention: Double phototherapy (n=41)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Single phototherapy (n=42)
Number of subjects: 83
Study: 26704141

Group type: EXPERIMENTAL
Intervention: Air Optix Aqua multifocal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PureVision 2 for Presbyopia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acuvue OASYS for Presbyopia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Biofinity multifocal
Number of subjects: 35

Group type: COMPARATOR
Intervention: Monovision with Biofinity
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All lenses
Number of subjects: 35
Study: 28033526

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC-1) with TPF ± cetuximab
Number of subjects: 52
Study: 23485078

Group type: EXPERIMENTAL
Intervention: Prednisone monotherapy (1‐2 mg/kg/d; maximal total dose, ≤60 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prednisone + fluvastatin (5 mg/d if aged <5 years; 10 mg/d if aged ≥5 years)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy children without evidence of renal, hepatobiliary, cardiovascular, or hematologic disease)
Number of subjects: 60
Study: 21075564

Group type: EXPERIMENTAL
Intervention: Cocaine abstinent patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non‐using controls
Number of subjects: 43
Study: 18800069

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg per day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 17470689

Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents (AAs) including bevacizumab, SU11248, and BAY‐43‐9006 combined with radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study: 15055891

Group type: EXPERIMENTAL
Intervention: bupivacaine 7.5 mg combined with S(+) ketamine 0.1 mg kg(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: bupivacaine 10 mg
Number of subjects: 40
Study: 11738125

Group type: EXPERIMENTAL
Intervention: Intense Tai Chi (48 weeks, twice per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wellness education program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intense Tai Chi
Number of subjects: 0
Study: 9625322

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 7602025

Group type: EXPERIMENTAL
Intervention: Metoprolol, > or = 25 mg/day for at least 5 days after MI
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no beta-blocker therapy)
Number of subjects: 118
Study: 2113094

Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 23

Group type: COMPARATOR
Intervention: HATG
Number of subjects: 23
Study: 371421

Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and short-term interpersonal psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy alone (tricyclic antidepressants)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychotherapy alone (various psychotherapies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonscheduled supportive psychotherapy
Number of subjects: 0
Study: 31520309

Group type: EXPERIMENTAL
Intervention: Ferrous Ascorbate (FA)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Iron Polymaltose Complex (IPC)
Number of subjects: 125
Study: 29375198

Group type: EXPERIMENTAL
Intervention: Oligomeric proanthocyanidin nutritional supplement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 25881322

Group type: COMPARATOR
Intervention: Locomotor treadmill training (LTT) alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: LTT combined with Tizanidine (TizLTT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both LTT and TizLTT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TizLTT
Number of subjects: 48
Study: 22778053

Group type: EXPERIMENTAL
Intervention: Individualized home-based training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20739195

Group type: EXPERIMENTAL
Intervention: 1mg INT131 besylate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10mg INT131 besylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19577749

Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 mug)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16752617

Group type: EXPERIMENTAL
Intervention: Pathways implemented through the Medical Patient Management program in the test group (n = 50)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (n = 41)
Number of subjects: 91
Study: 14711717

Group type: EXPERIMENTAL
Intervention: Vitamin E (500 IU daily)
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study: 11699480

Group type: EXPERIMENTAL
Intervention: Dual acid-etched implants
Number of subjects: 97

Group type: COMPARATOR
Intervention: Machined-surfaced implants
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Dual acid-etched implants in poor quality or soft bone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Machined-surfaced implants in poor quality or soft bone
Number of subjects: 97
Study: 9441094

Group type: EXPERIMENTAL
Intervention: Chinese rifapentine
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Second batch of Chinese rifapentine
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Increased dose of last two batches of Chinese rifapentine (750 mg to 900 mg)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: All batches of rifapentine
Number of subjects: 287
Study: 7961057

Group type: EXPERIMENTAL
Intervention: Ceruletide (6.75 micrograms)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ceruletide (6 micrograms)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 48

Group type: COMPARATOR
Intervention: Regular breakfast
Number of subjects: 48

Group type: COMPARATOR
Intervention: Opulent meal
Number of subjects: 48
Study: 2239975

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IV IgG) 1 g/kg administered every 30 days for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous placebo (1% albumin solution) administered every 30 days for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both IV IgG and placebo groups
Number of subjects: 30
Study: 79080

Group type: EXPERIMENTAL
Intervention: Oral electrolyte solutions containing sucrose
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oral electrolyte solutions containing glucose
Number of subjects: 51
Study: 31652479

Group type: EXPERIMENTAL
Intervention: 17‐OHPC (250 mg IM weekly)
Number of subjects: 1708
Study: 30286483

Group type: EXPERIMENTAL
Intervention: Magnesium and Vitamin E co-supplementation (250 mg/day magnesium plus 400 mg/day vitamin E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28753100

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CAF + CM
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CAF + EMD
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CAF + CM + EMD
Number of subjects: 68
Study: 25547929

Group type: EXPERIMENTAL
Intervention: Interactive safety decision aid
Number of subjects: 708

Group type: COMPARATOR
Intervention: Usual safety planning resources
Number of subjects: 708
Study: 24138348

Group type: EXPERIMENTAL
Intervention: Energize program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 21473754

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (CBT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Discussion forum (Control)
Number of subjects: 85
Study: 19126587

Group type: EXPERIMENTAL
Intervention: Acupuncture (10 sessions)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Control (usual care only)
Number of subjects: 981
Study: 16153646

Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Number of subjects: 404
Study: 15350372

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m² intravenously over 3 hours) and Carboplatin (AUC 6) every 3 weeks
Number of subjects: 6
Study: 11347795

Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 mg bid)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Methylphenidate and Placebo
Number of subjects: 5
Study: 9389398

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with division of short gastric vessels (SGVs) (52 patients)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication without division of short gastric vessels (SGVs) (50 patients)
Number of subjects: 102
Study: 8110432

Group type: EXPERIMENTAL
Intervention: Sodium chloride (200 mmol/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium citrate (200 mmol/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium chloride and sodium citrate
Number of subjects: 15
Study: 3816107

Group type: EXPERIMENTAL
Intervention: Cholestyramine 1.0 g
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride 1.3 g
Number of subjects: 40
Study: 29196864

Group type: EXPERIMENTAL
Intervention: Ball-tapping-exercise intervention (15 min of tapping a plastic ball)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Story-time (control condition)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ball-tapping-exercise intervention
Number of subjects: 30
Study: 27846175

Group type: EXPERIMENTAL
Intervention: Absorbable tacker fixation (AT group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonabsorbable tacker fixation (NAT group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (AT and NAT)
Number of subjects: 90
Study: 24547604

Group type: EXPERIMENTAL
Intervention: Supplementary transcatheter arterial embolization (STAE) within 24 hours from therapeutic endoscopy
Number of subjects: 831

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 831

Group type: COMPARATOR
Intervention: Peptic ulcer bleeding patients
Number of subjects: 831

Group type: COMPARATOR
Intervention: Matched control group of 2224 individuals
Number of subjects: 831
Study: 23690556

Group type: EXPERIMENTAL
Intervention: LightBeer+25
Number of subjects: 7

Group type: COMPARATOR
Intervention: Beer
Number of subjects: 7

Group type: COMPARATOR
Intervention: Beer+25
Number of subjects: 7